Cerus Corporation reiterated product revenue guidance for the full year 2024. The company expects full-year 2024 product revenue will be in the range of $172 million to $175 million. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8 million to $10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.67 USD | -4.57% | -0.60% | -22.69% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.69% | 324M | |
+12.37% | 129B | |
-9.23% | 10.77B | |
+2.17% | 9.05B | |
+18.79% | 7.38B | |
+20.77% | 4.88B | |
+6.97% | 3.41B | |
-1.41% | 3.07B | |
-5.07% | 2.24B | |
-4.22% | 2.12B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024